Current Status and Emerging Trends in Colorectal Cancer Screening and Diagnostics
Open accessThe DOI matches its Crossref record; 113 of the 113 references it cites were found in a registry or an index.
Abstract
Colorectal cancer (CRC) is a prevalent and potentially fatal disease categorized based on its high incidences and mortality rates, which raised the need for effective diagnostic strategies for the early detection and management of CRC. While there are several conventional cancer diagnostics available, they have certain limitations that hinder their effectiveness. Significant research efforts are currently being dedicated to elucidating novel methodologies that aim at comprehending the intricate molecular mechanism that underlies CRC. Recently, microfluidic diagnostics have emerged as a pivotal solution, offering non-invasive approaches to real-time monitoring of disease progression and treatment response. Microfluidic devices enable the integration of multiple sample preparation steps into a single platform, which speeds up processing and improves sensitivity. Such advancements in diagnostic technologies hold immense promise for revolutionizing the field of CRC diagnosis and enabling efficient detection and monitoring strategies. This article elucidates several of the latest developments in microfluidic technology for CRC diagnostics. In addition to the advancements in microfluidic technology for CRC diagnostics, the integration of artificial intelligence (AI) holds great promise for further enhancing diagnostic capabilities. Advancements in microfluidic systems and AI-driven approaches can revolutionize colorectal cancer diagnostics, offering accurate, efficient, and personalized strategies to improve patient outcomes and transform cancer management.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




![Figure 5 Schematic illustration (A1,A2) Integrated microfluidic device for CTC enrichment and analysis (B1,B2) Development of Integrated Microfluidic Device for Simultaneous Enrichment and Analysis of Circulating Tumor Cells, (C1) Comparative Immuno-staining Analysis of Captured Cells in PBS and Human Blood Samples [81]. (Reproduced with permission from Su, W.; Yu, H.; Jiang, L.; Chen, W.; Li, H.; Qin, J, Disease Markers; published by Hindawi, 2019).](https://figures.cochat.ai/paper-figures/1fd715b4e8834ceca3a27c166a357f64/current-status-and-emerging-trends-in-colorectal-cancer-screening-and-figure-5.jpg)
![Figure 6 Schematic representation illustrating the underlying mechanism of enzyme-aided fluorescence amplification based on GO-DNA aptamer interactions for exosome detection (Image taken from: Reproduced with permission from Wang, H.; Chen, H.; Huang, Z.; Li, T.; Deng, A.; Kong, J. Ta-lanta; published by Elsevier, 2018 [87].](https://figures.cochat.ai/paper-figures/82bd840d41c14274bae7fb6369102714/current-status-and-emerging-trends-in-colorectal-cancer-screening-and-figure-6.jpg)



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global colorectal cancer burden in 2020 and projections to 2040
Xi, Y., & Xu, P. (2021) · Translational Oncology · doi:10.1016/j.tranon.2021.101174 · Cited by 2,434 · cited 1×
“Recent epidemiological data from 2020 to 2021 reported a mortality rate of 9.4%, accompanied by a noteworthy increase in incidents among the elderly [2].”
BackgroundInfluentialEpidemiology of colorectal cancer: incidence, mortality, survival, and risk factors
Rawla, P., Sunkara, T., & Barsouk, A. (2019) · Gastroenterology Review · doi:10.5114/pg.2018.81072 · Cited by 2,323
Microfluidic diagnostic technologies for global public health
Yager, P., Edwards, T., Fu, E., Helton, K., Nelson, K., Tam, M. R., & Weigl, B. H. (2006) · Nature · doi:10.1038/nature05064 · Cited by 1,979
Multitarget Stool DNA Testing for Colorectal-Cancer Screening
Imperiale, T. F., Ransohoff, D. F., Itzkowitz, S. H., Levin, T. R., Lavin, P., Lidgard, G. P., Ahlquist, D. A., & Berger, B. M. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1311194 · Cited by 1,900 · cited 1×
“…can identify specific molecular changes that are indicative of CRC or By analyzing alterations in genes or DNA regions known to be linked to CRC, these tests can identify speci fi c molecular changes that are indicative of CRC or advanced adenomas. biomarkers associated with CRC development [21].”
BackgroundTrevethan, R. (2017) · Frontiers in Public Health · doi:10.3389/fpubh.2017.00307 · Cited by 1,616
Ethical and legal challenges of artificial intelligence-driven healthcare
Gerke, S., Minssen, T., & Cohen, G. (2020) · Artificial Intelligence in Healthcare · doi:10.1016/b978-0-12-818438-7.00012-5 · Cited by 1,170 · cited 1×
“Addressing these concerns effectively is imperative to facilitate adoption [111].”
BackgroundLin, J. S., Bowles, E. J. A., Williams, S. B., & Morrison, C. C. (2017) · JAMA · doi:10.1001/jama.2017.0562 · Cited by 1,082
Accuracy of Fecal Immunochemical Tests for Colorectal Cancer: Systematic Review and Meta-analysis
Lee, J. K., Liles, E. G., Bent, S., Levin, T. R., & Corley, D. A. (2014) · Annals of Internal Medicine · doi:10.7326/m13-1484 · Cited by 707 · cited 1×
“…demonstrates up to 79% sensitivity and 94% specificity, reflecting its efficacy as a screening modality for detecting CRC prior to symptoms [19] and contributing to Among these, FIT demonstrates up to 79% sensitivity and 94% speci fi city, re fl ecting its e ffi cacy as a robust screening…”
BackgroundLin, J. S., Piper, M. A., Perdue, L. A., Rutter, C. M., Webber, E. M., O’Connor, E., Smith, N., & Whitlock, E. P. (2016) · JAMA · doi:10.1001/jama.2016.3332 · Cited by 693
Colorectal cancer screening: An updated review of the available options
Issa, I. A., & Noureddine, M. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i28.5086 · Cited by 572
Adherence to Colorectal Cancer Screening: A Randomized Clinical Trial of Competing Strategies
Vijan, S. (2012) · Archives of Internal Medicine · doi:10.1001/archinternmed.2012.332 · Cited by 552 · cited 1×
“Consequently, in programmatic screening endeavors, colonoscopy is best used as the second step in a two-stage screening cascade [27].”
MethodArtificial intelligence in cancer target identification and drug discovery
You, Y., Lai, X., Pan, Y., Zheng, H., Vera, J., Liu, S., Deng, S., & Zhang, L. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00994-0 · Cited by 435
Zorzi, M., Fedeli, U., Schievano, E., Bovo, E., Guzzinati, S., Baracco, S., Fedato, C., Saugo, M., & Dei Tos, A. P. (2015) · Gut · doi:10.1136/gutjnl-2014-307508 · Cited by 302 · cited 1×
“…symptoms [19] and contributing to Among these, FIT demonstrates up to 79% sensitivity and 94% speci fi city, re fl ecting its e ffi cacy as a robust screening modality for detecting CRC prior to symptoms [19] and contributing to a 22% reduction in CRC incidences [20]. reduction in CRC incidences [20].”
BackgroundPrognostic and Predictive Molecular Biomarkers for Colorectal Cancer: Updates and Challenges
Koncina, E., Haan, S., Rauh, S., & Letellier, E. (2020) · Cancers · doi:10.3390/cancers12020319 · Cited by 259 · cited 2×
“Other Cancer-Related Biomarkers Detection For instance, efforts have been focused on the monitoring of changes in the mechanobi-ology of CRC cells using on-chip techniques [90]. malignancy-related pharmacological platforms treatment monitoring, and personalized therapeutic interventions [79,89].”
BackgroundBiomarkers in Colorectal Cancer: Current Research and Future Prospects
Ogunwobi, O. O., Mahmood, F., & Akingboye, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155311 · Cited by 250 · cited 2×
“…acids, mRNA expression pro fi les, proteins, and other substances found in bodily fl uids, o ff er valuable clinical insights to physicians regarding disease status and aid in making informed decisions regarding subsequent treatment strategies [88]. mechanical forces and monitoring their responses.”
BackgroundColorectal cancer: A health and economic problem
Klimeck, L., Heisser, T., Hoffmeister, M., & Brenner, H. (2023) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2023.101839 · Cited by 241
Blood CEA levels for detecting recurrent colorectal cancer
Nicholson, B. D., Shinkins, B., Pathiraja, I., Roberts, N. W., James, T. J., Mallett, S., Perera, R., Primrose, J. N., & Mant, D. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011134.pub2 · Cited by 226 · cited 2×
“Nevertheless, CEA testing remains valuable for monitoring treatment response following chemotherapy or for screening disease recurrence after completing the treatment regimen [44].”
BackgroundMethodMicrofluidic Point-of-Care Devices: New Trends and Future Prospects for eHealth Diagnostics
Mejía-Salazar, J. R., Rodrigues Cruz, K., Materón Vásques, E. M., & Novais de Oliveira Jr., O. (2020) · Sensors · doi:10.3390/s20071951 · Cited by 225 · cited 1×
“These compact, user-friendly devices can swiftly ascertain CRC-specific biomarkers, thereby enabling early diagnosis even in resource-constrained locales or remote geographical areas [100].”
BackgroundExosomes as potential sources of biomarkers in colorectal cancer
Xiao, Y., Zhong, J., Zhong, B., Huang, J., Jiang, L., Jiang, Y., Yuan, J., Sun, J., Dai, L., Yang, C., et al. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.01.033 · Cited by 187 · cited 1×
“Researchers are actively engaged in delineating distinctive microRNA profiles and protein markers encapsulated within these exosomes, thereby facilitating the development of highly sensitive and specific diagnostic assays [45,46].”
BackgroundAccurate diagnosis of colorectal cancer based on histopathology images using artificial intelligence
Wang, K. S., Yu, G., Xu, C., Meng, X. H., Zhou, J., Zheng, C., Deng, Z., Shang, L., Liu, R., Su, S., et al. (2021) · BMC Medicine · doi:10.1186/s12916-021-01942-5 · Cited by 176
A Simplified, Noninvasive Stool DNA Test for Colorectal Cancer Detection
Itzkowitz, S., Brand, R., Jandorf, L., Durkee, K., Millholland, J., Rabeneck, L., Schroy, P. C., Sontag, S., Johnson, D., Markowitz, S., et al. (2008) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2008.02088.x · Cited by 161
Buse, J. D., & El‐Aneed, A. (2010) · Nanomedicine · doi:10.2217/nnm.10.107 · Cited by 155 · cited 1×
“As with many other nanoparticles, lipid-based nanoparticles can be functionalized with specific targeting ligands or antibodies that selectively recognize CRC biomarkers or tumor-associated antigens [70].”
BackgroundApplications of Microfluidics and Organ-on-a-Chip in Cancer Research
Regmi, S., Poudel, C., Adhikari, R., & Luo, K. Q. (2022) · Biosensors · doi:10.3390/bios12070459 · Cited by 143 · cited 1×
“These miniaturized systems offer numerous advantages, including reduced sample and reagent consumption, accelerated reaction times, enhanced sensitivity, and portability [74].”
BackgroundWang, H., Chen, H., Huang, Z., Li, T., Deng, A., & Kong, J. (2018) · Talanta · doi:10.1016/j.talanta.2018.02.083 · Cited by 139 · cited 1×
“To further increase the sensitivity of exosome detection, a novel method combines fluorescence signal amplification aided by the DNase I enzyme and graphene oxide-DNA aptamer interactions to capture CRC exosomes [87].”
MethodCost-Effectiveness of Colorectal Cancer Screening Strategies—A Systematic Review
Ran, T., Cheng, C.-Y., Misselwitz, B., Brenner, H., Ubels, J., & Schlander, M. (2019) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2019.01.014 · Cited by 139 · cited 1×
“The technique serves as an effective screening tool for detecting CRC and its precursors, particularly in the distal colon [28].”
MethodLab-on-Chip for Exosomes and Microvesicles Detection and Characterization
Chiriacò, M. S., Bianco, M., Nigro, A., Primiceri, E., Ferrara, F., Romano, A., Quattrini, A., Furlan, R., Arima, V., & Maruccio, G. (2018) · Sensors · doi:10.3390/s18103175 · Cited by 130 · cited 1×
“Exosome detection chips commonly utilize diverse functional components and techniques to optimize the efficiency and specificity of exosome capture and analysis [84].”
BackgroundDuffy, M. J., van Rossum, L. G. M., van Turenhout, S. T., Malminiemi, O., Sturgeon, C., Lamerz, R., Nicolini, A., Haglund, C. H., Holubec, L., Fraser, C. G., et al. (2010) · International Journal of Cancer · doi:10.1002/ijc.25654 · Cited by 124
Colorectal cancer, screening and primary care: A mini literature review
Hadjipetrou, A., Anyfantakis, D., Galanakis, C., Kastanakis, M., & Kastanakis, S. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i33.6049 · Cited by 121 · cited 1×
“As the gold standard screening and diagnostic modality, this technique enables the direct visualization and thorough examination of the entire colon and rectum, facilitating the identification of early-stage CRC lesions [26].”
MethodThe global challenge of colorectal cancer
Guren, M. G. (2019) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(19)30329-2 · Cited by 121
The role of AI technology in prediction, diagnosis and treatment of colorectal cancer
Yu, C., & Helwig, E. J. (2021) · Artificial Intelligence Review · doi:10.1007/s10462-021-10034-y · Cited by 117 · cited 1×
“By incorporating AI into the diagnostic process, issues of variability in traditional evaluations can be addressed, leading to more dependable and consistent diagnostic assessments and potentially improving patient outcomes [95].”
BackgroundGogoi, P., Sepehri, S., Zhou, Y., Gorin, M. A., Paolillo, C., Capoluongo, E., Gleason, K., Payne, A., Boniface, B., Cristofanilli, M., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0147400 · Cited by 104 · cited 2×
“To enhance the accessibility of the platform to minimally trained hands, others designed a microfluidic platform that incorporated an antibody-coated surface for specific CTC capture and integrated automation for enhanced efficiency and reproducibility [82].”
MethodMicrofluidic Technology for Clinical Applications of Exosomes
Iliescu, F., Vrtačnik, D., Neuzil, P., & Iliescu, C. (2019) · Micromachines · doi:10.3390/mi10060392 · Cited by 99 · cited 1×
“These innovative chips offer rapid, sensitive, and high-throughput detection of exosomes, thereby presenting new avenues for diagnostics, biomarker discovery, and therapeutic applications [83].”
BackgroundChallenges in the management of colorectal cancer in low- and middle-income countries
Khan, S. Z., & Lengyel, C. G. (2023) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2023.100705 · Cited by 99 · cited 1×
“Securing regulatory clearance or approval is a protracted and resource-intensive endeavor [108].”
BackgroundMultifunctional Carbon-Based Nanomaterials: Applications in Biomolecular Imaging and Therapy
Zhang, Y., Wu, M., Wu, M., Zhu, J., & Zhang, X. (2018) · ACS Omega · doi:10.1021/acsomega.8b01071 · Cited by 98 · cited 1×
“…a large surface area and high electrical conductivity, which makes them ideal for functionalization with specific targeting ligands or biomolecules [63], and they can be integrated with electrical-based sensors such as impedance and electro-chemical sensors that are common in point-of-care…”
BackgroundMultitarget Stool DNA Test Performance in an Average-Risk Colorectal Cancer Screening Population
Bosch, L. J. W., Melotte, V., Mongera, S., Daenen, K. L. J., Coupé, V. M. H., van Turenhout, S. T., Stoop, E. M., de Wijkerslooth, T. R., Mulder, C. J. J., Rausch, C., et al. (2019) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000000445 · Cited by 98 · cited 2×
“…symptoms [19] and contributing to Among these, FIT demonstrates up to 79% sensitivity and 94% speci fi city, re fl ecting its e ffi cacy as a robust screening modality for detecting CRC prior to symptoms [19] and contributing to a 22% reduction in CRC incidences [20]. reduction in CRC incidences [20].”
BackgroundTrends in targeted delivery of nanomaterials in colon cancer diagnosis and treatment
Khan, F. A., Albalawi, R., & Pottoo, F. H. (2022) · Medicinal Research Reviews · doi:10.1002/med.21809 · Cited by 95 · cited 2×
“This is attributed to the unique physicochemical properties inherent in nanomaterials, which enable efficient biomarker capture and amplification due to their substantial surface area-to-volume ratio [54,55].”
BackgroundAdvances in tests for colorectal cancer screening and diagnosis
Chan, S. C. H., & Liang, Q. (2022) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2022.2065197 · Cited by 92
Recent advances for cancer detection and treatment by microfluidic technology, review and update
Bargahi, N., Ghasemali, S., Jahandar-Lashaki, S., & Nazari, A. (2022) · Biological Procedures Online · doi:10.1186/s12575-022-00166-y · Cited by 91
Recent Advances of Utilizing Artificial Intelligence in Lab on a Chip for Diagnosis and Treatment
Zare Harofte, S., Soltani, M., Siavashy, S., & Raahemifar, K. (2022) · Small · doi:10.1002/smll.202203169 · Cited by 91 · cited 1×
“By considering factors such as genetic profiles, treatment response data, and trends in biomarker levels, AI algorithms can proffer personalized therapeutic recommendations, optimizing the likelihood of favorable treatment outcomes while minimizing the occurrence of adverse side effects [101].”
BackgroundThakur, N., Yoon, H., & Chong, Y. (2020) · Cancers · doi:10.3390/cancers12071884 · Cited by 89
Microfluidics as an Enabling Technology for Personalized Cancer Therapy
Mathur, L., Ballinger, M., Utharala, R., & Merten, C. A. (2019) · Small · doi:10.1002/smll.201904321 · Cited by 88
Clinical research and medical care: towards effective and complete integration
Sacristán, J. A. (2015) · BMC Medical Research Methodology · doi:10.1186/1471-2288-15-4 · Cited by 85 · cited 1×
“Clinicians are predisposed to demand a substantial of evidence before considering the assimilation of novel technologies to assure enhanced patient outcomes [109].”
BackgroundNanotechnology for colorectal cancer detection and treatment
Gogoi, P., Kaur, G., & Singh, N. K. (2022) · World Journal of Gastroenterology · doi:10.3748/wjg.v28.i46.6497 · Cited by 82 · cited 1×
“REVIEW Furthermore, these technologies can be customized to accommodate diverse sample types, including blood, tissue, and stool, extending their applicability in CRC diagnostics [56,57].”
Cahill, R. A., O’Shea, D. F., Khan, M. F., Khokhar, H. A., Epperlein, J. P., Aonghusa, P. M., Nair, R. P., & Zhuk, S. M. (2020) · British journal of surgery · doi:10.1093/bjs/znaa004 · Cited by 81
Towards Novel Non-Invasive Colorectal Cancer Screening Methods: A Comprehensive Review
Ferrari, A., Neefs, I., Hoeck, S., Peeters, M., & Van Hal, G. (2021) · Cancers · doi:10.3390/cancers13081820 · Cited by 80 · cited 2×
“Ensuring high specificity in CRC screening can better ensure that medical resources are allocated to only patients with positive results [9].”
BackgroundBiomarker-Based Prediction of Response to Therapy for Colorectal Cancer
Ross, J. S., Torres‐Mora, J., Wagle, N., Jennings, T. A., & Jones, D. (2010) · American Journal of Clinical Pathology · doi:10.1309/ajcp2y8ktdpoaorh · Cited by 79 · cited 1×
“…including circulating tumor DNA (ctDNA), microRNAs, DNA methylation markers, and protein-based markers. ctDNA, fragments of tumor-derived DNA present in the bloodstream, enables the detection of specific genetic mutations or alterations associated with CRC, as represented in Figure 3 [40–42].”
BackgroundBhuiyan, N. H., Hong, J. H., Uddin, M. J., & Shim, J. S. (2022) · Analytical Chemistry · doi:10.1021/acs.analchem.1c04827 · Cited by 77 · cited 1×
“Such real-time feedback has the potential to be invaluable in facilitating prompt clinical decision-making for individuals afflicted by CRC [98,99].”
BackgroundChinnappan, R., Ramadan, Q., & Zourob, M. M. (2022) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2022.114856 · Cited by 74
Electrochemical Biosensors for Determination of Colorectal Tumor Biomarkers
Quinchía, J., Echeverri, D., Cruz‐Pacheco, A. F., Celis, M. E. M., & Orozco, J. (2020) · Micromachines · doi:10.3390/mi11040411 · Cited by 72 · cited 1×
“This amalgamation, therefore, holds the promise of substantially augmenting the precision of CRC detection, enabling the identification of specific biomarkers within bodily fluids or tissue specimens [96,97].”
BackgroundKamel, F., Eltarhoni, K., Nisar, P. J., & Soloviev, M. (2022) · Cancers · doi:10.3390/cancers14081889 · Cited by 72 · cited 1×
“As a result, there is a growing demand for novel and patient-friendly approaches that are non-invasive or minimally invasive, aimed at improving patient acceptance and adherence to recommended screening protocols [38].”
BackgroundLab-on-a-chip systems for cancer biomarker diagnosis
Özyurt, C., Uludağ, İ., İnce, B., & Sezgintürk, M. K. (2023) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2023.115266 · Cited by 72 · cited 1×
“This amalgamation, therefore, holds the promise of substantially augmenting the precision of CRC detection, enabling the identification of specific biomarkers within bodily fluids or tissue specimens [96,97].”
BackgroundLi, P., Chen, J., Chen, Y., Song, S., Huang, X., Yang, Y., Li, Y., Tong, Y., Yan, X., Li, J., et al. (2023) · Small · doi:10.1002/smll.202207381 · Cited by 72
The Use of Microfluidic Technology for Cancer Applications and Liquid Biopsy
Kulasinghe, A., Wu, H., Punyadeera, C., & Warkiani, M. E. (2018) · Micromachines · doi:10.3390/mi9080397 · Cited by 71 · cited 1×
“…(CTCs) and cell-free DNA (cfDNA) from blood specimens, providing a non-invasive avenue for monitoring cancer progression and treatment response [76,77] detection of genetic mutations, tumor markers, and other biomarkers associated with colorectal cancer, thereby enabling early-stage diagnosis and…”
BackgroundMatos, A. I., Carreira, B., Peres, C., Moura, L. I. F., Conniot, J., Fourniols, T., Scomparin, A., Martínez-Barriocanal, Á., Arango, D., Conde, J. P., et al. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.06.017 · Cited by 68 · cited 1×
“The unique properties and capabilities of nanomaterials offer new avenues for the sensitive and specific detection of CRC biomarkers, enabling early diagnosis and personalized treatment strategies, as represented in Figure 4 [53].”
BackgroundBlood CEA levels for detecting recurrent colorectal cancer
Nicholson, B. D., Shinkins, B., Pathiraja, I., Roberts, N. W., James, T. J., Mallett, S., Perera, R., Primrose, J. N., & Mant, D. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011134 · Cited by 66
Chen, H., Shi, J., Lu, M., Li, Y., Du, L., Liao, X., Wei, D., Dong, D., Gao, Y. C., Zhu, C. Y., et al. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2022.08.003 · Cited by 66 · cited 1×
“A recent study reported [37] a comparative analysis of a colonoscopy, a fecal immunochemical test, and a risk-adapted approach in a colorectal cancer screening trial (TARGET-C) to compare three distinct methods of CRC screening.”
MethodCai, H.-K. (2012) · World Journal of Gastroenterology · doi:10.3748/wjg.v18.i42.6148 · Cited by 65 · cited 2×
“The comparable staining efficacy between activated carbon nanoparticle suspension and methylene blue indicated their effectiveness in highlighting the lymph nodes, suggesting that activated carbon nanoparticles are a promising alternative to methylene blue for lymph node staining in CRC [66].”
BackgroundExosomes As Potential Biomarkers and Targeted Therapy in Colorectal Cancer: A Mini-Review
Hon, K. W., Abu, N., Mutalib, N. A., & Jamal, R. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00583 · Cited by 64 · cited 1×
“Researchers are actively engaged in delineating distinctive microRNA profiles and protein markers encapsulated within these exosomes, thereby facilitating the development of highly sensitive and specific diagnostic assays [45,46].”
BackgroundPickhardt, P. J. (2016) · Abdominal Radiology · doi:10.1007/s00261-016-0798-4 · Cited by 63 · cited 1×
“Conversely, non-invasive tests employ approaches such as fecal occult blood test (FOBT), fecal immunochemical test (FIT), and stool DNA test (MT-sDNA) [17].”
MethodAdvances in integrated digital microfluidic platforms for point-of-care diagnosis: a review
Zhang, Y., & Liu, Y. (2022) · Sensors & Diagnostics · doi:10.1039/d2sd00031h · Cited by 63
Self-citationEstablishment of Colorectal Cancer Organoids in Microfluidic-Based System
Pinho, D., Santos, D., Vila, A., & Carvalho, S. (2021) · Micromachines · doi:10.3390/mi12050497 · Cited by 59 · cited 3×
“Other Cancer-Related Biomarkers Detection For instance, efforts have been focused on the monitoring of changes in the mechanobi-ology of CRC cells using on-chip techniques [90]. malignancy-related pharmacological platforms treatment monitoring, and personalized therapeutic interventions [79,89].”
BackgroundBlood-based DNA Methylation Biomarkers for Early Detection of Colorectal Cancer
Dong, L., & Ren, H. (2018) · Journal of Proteomics & Bioinformatics · doi:10.4172/jpb.1000477 · Cited by 54 · cited 2×
“…tool for CRC in global clinical practice due to its potential elevation in various in fl ammatory conditions, such as diverticulitis and in-fl Protein-based markers, such as carcinoembryonic antigen (CEA), have been extensively employed for CRC screening and therapeutic response monitoring [43].”
BackgroundHighly fluorescent carbon dots as novel theranostic agents for biomedical applications
Wan, J., Zhang, X., Fu, K., Zhang, X., Shang, L., & Su, Z. (2021) · Nanoscale · doi:10.1039/d1nr03740d · Cited by 53 · cited 2×
“Quantum dots (QDs) are nano-scale fluorescent semiconductor crystals renowned for their unique optical characteristics, especially their exceptional brightness, photo stability, and tunable emission spectra, enabling multiplexed imaging capabilities [58].”
BackgroundHuang, Y., Wei, P., Ho, C., & Yeh, C. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11040913 · Cited by 53 · cited 1×
“This escalating occurrence of CRC has been attributed to various factors, such as aging and lifestyles such as sedentary habits, suboptimal dietary choices, and tobacco use [4,5].”
BackgroundImperiale, T. F., Kisiel, J. B., Itzkowitz, S. H., Scheu, B., Duimstra, E. K., Statz, S., Berger, B. M., & Limburg, P. J. (2021) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-20-0294 · Cited by 50
A Review on the Role of lipid-based Nanoparticles in Medical Diagnosis and Imaging
Mirahadi, M., Ghanbarzadeh, S., Ghorbani, M., Gholizadeh, A., & Hamishehkar, H. (2018) · Therapeutic Delivery · doi:10.4155/tde-2018-0020 · Cited by 48 · cited 1×
“Lipid-based nanoparticles, which comprise lipid materials such as phospholipids or cholesterol, offer several advantages for CRC diagnosis [68,69].”
BackgroundProbing the colorectal cancer proteome for biomarkers: Current status and perspectives
Lee, P. Y., Chin, S., Low, T. Y., & Jamal, R. (2018) · Journal of Proteomics · doi:10.1016/j.jprot.2018.06.014 · Cited by 47 · cited 1×
“Through the integration of advancements in molecular biology and diagnostic technologies, ongoing research endeavors aim to identify novel markers and optimize their clinical applicability [47,48].”
BackgroundArechederra, M., Avila, M. A., & Berasain, C. (2020) · Advances in Laboratory Medicine / Avances en Medicina de Laboratorio · doi:10.1515/almed-2020-0009 · Cited by 43 · cited 1×
“…including circulating tumor DNA (ctDNA), microRNAs, DNA methylation markers, and protein-based markers. ctDNA, fragments of tumor-derived DNA present in the bloodstream, enables the detection of specific genetic mutations or alterations associated with CRC, as represented in Figure 3 [40–42].”
BackgroundLiu, Y., Schulze‐Makuch, D., Vera, J.-P. P. D., Cockell, C. S., Leya, T., Baqué, M., & Walther-Antonio, M. R. S. (2018) · Micromachines · doi:10.3390/mi9080367 · Cited by 43
Self-citationRecent advances in colorectal cancer screening
Li, D. (2018) · Chronic Diseases and Translational Medicine · doi:10.1016/j.cdtm.2018.08.004 · Cited by 42 · cited 1×
“Therefore, the discriminatory power to distinguish individuals with and without CRC is not robust until the onset of primary symptoms, which can delay diagnosis and treatment [50].”
BackgroundYan, J., Xue, F., Chen, H., Wu, X., Zhang, H., Chen, G., Lu, J., Cai, L., Gao, X., Deng, Z., et al. (2014) · Surgical Endoscopy · doi:10.1007/s00464-014-3608-5 · Cited by 40 · cited 2×
“Notably, the carbon nanoparticle-guided sentinel lymph node biopsy exhibited a superior detection rate for lymph node metastasis compared to conventional histopathological examination, demonstrating heightened sensitivity of 91.67% and a specificity value of 100% [64].”
BackgroundInfluentialGazouli, M. (2012) · World Journal of Gastroenterology · doi:10.3748/wjg.v18.i32.4419 · Cited by 40 · cited 2×
“For instance, Gazouli et al. [60] developed a QD-labeled magnetic immunoassay (QD-MIA) technology that combines QDs and magnetic separation strategies to detect circulating CRC cells.”
BackgroundMethodCost-Effectiveness Analysis of Colorectal Cancer Screening: A Systematic Review
Khalili, F., Najafi, B., Mansour‐Ghanaei, F., Yousefi, M., Abdollahzad, H., & Motlagh, A. G. (2020) · Risk Management and Healthcare Policy · doi:10.2147/rmhp.s262171 · Cited by 39 · cited 1×
“Furthermore, disparities in accessibility to these technologies in distinct healthcare settings or regions can exert a detrimental influence on their integration [110].”
BackgroundChand, M., Keller, D. S., Mirnezami, R., Bullock, M. D., Bhangu, A. A., Moran, B. J., Tekkis, P. P., Brown, G. M., Mirnezami, A., & Berho, M. E. (2018) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v10.i7.145 · Cited by 39
Promising Epigenetic Biomarkers for the Early Detection of Colorectal Cancer: A Systematic Review
Anghel, S. A., Ioniță-Mîndrican, C.-B., Luca, I., & Pop, A. L. (2021) · Cancers · doi:10.3390/cancers13194965 · Cited by 38 · cited 1×
“The incorporation of these biomarkers into routine clinical practice has the potential to revolutionize CRC management, fostering improved patient outcomes, refined treatment decisions, and a more targeted approach to combating this complex disease [49].”
BackgroundGalanopoulos, M., Tsoukalas, N., Papanikolaou, I. S., Tolia, M., Gazouli, M., & Mantzaris, G. J. (2017) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v9.i4.142 · Cited by 38
Wang, Q., Chen, E., Cai, Y., Chen, C., Jin, W.-X., Zheng, Z., Jin, Y.-X., Chen, Y., Zhang, X., & Li, Q. (2016) · World Journal of Surgical Oncology · doi:10.1186/s12957-016-0987-1 · Cited by 37 · cited 2×
“In another study by Wang et al. [67] prior to surgery, carbon nanoparticles were injected into the submucosal layer surrounding the tumor site during endoscopic examination.”
BackgroundMethodCotter, T. G., Burger, K. N., Devens, M. E., Simonson, J. A., Lowrie, K. L., Heigh, R. I., Mahoney, D. W., Johnson, D. H., Ahlquist, D. A., & Kisiel, J. B. (2017) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-16-0800 · Cited by 37 · cited 1×
“Despite the numerous advantages of stool tests, this diagnostic modality demonstrates a sensitivity of only 42% in detecting advanced polyps [25].”
BackgroundLiu, Y., Jeraldo, P., Jang, J. S., Eckloff, B. W., Jen, J., & Walther-Antonio, M. R. S. (2019) · Analytical Chemistry · doi:10.1021/acs.analchem.8b04773 · Cited by 37
Self-citationOrtega, F. G., Gómez, G. E., Boni, C., García, I. C., Garrido-Navas, M. C., D'Vries, R. F., Vallejos, M. P. M., Serrano, M. J., Messina, G. A., Hernández, J. E., et al. (2022) · Talanta · doi:10.1016/j.talanta.2022.123766 · Cited by 33
Armistead, F. J., de Pablo, J. G., Gadêlha, H., Peyman, S. A., & Evans, S. D. (2020) · Scientific Reports · doi:10.1038/s41598-020-59952-x · Cited by 32 · cited 2×
“Other Cancer-Related Biomarkers Detection For instance, efforts have been focused on the monitoring of changes in the mechanobi-ology of CRC cells using on-chip techniques [90].”
MethodMolecular testing for colorectal cancer: Clinical applications
Имянитов, Е. Н., & Kuligina, E. S. (2021) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v13.i10.1288 · Cited by 32
Tang, Y., Duan, F., Zhou, A., Kanitthamniyom, P., Luo, S., Hu, X., Jiang, X., Vasoo, S. S., Zhang, X., & Zhang, Y. (2022) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10428 · Cited by 32
Noncathartic CT Colonography: Image Quality Assessment and Performance and in a Screening Cohort
Fletcher, J. G., Silva, A. C., Fidler, J. L., Cernigliaro, J. G., Manduca, A., Limburg, P. J., Wilson, L. A., Engelby, T. A., Spencer, G., Harmsen, W. S., et al. (2013) · American Journal of Roentgenology · doi:10.2214/ajr.12.9225 · Cited by 31 · cited 1×
“However, CT colonography has limitations in detecting sessile and flat polyps, which may lead to missed detections in certain cases [30–32].”
BackgroundNoor, J., Chaudhry, A., & Batool, S. (2023) · Cureus · doi:10.7759/cureus.39634 · Cited by 31 · cited 3×
“This section aims to elucidate the manifold applications and advantages of microfluidics in CRC diagnostics [75].”
BackgroundInfluentialSun, J., Zhang, S., Jiang, S., Bai, W., Liu, F., Yuan, H., Ji, J., Luo, J., Han, G., Chen, L., et al. (2016) · Journal of Biomedical Nanotechnology · doi:10.1166/jbn.2016.2285 · Cited by 29 · cited 1×
“The unique attributes of lipid-based nanoparticles, encompassing their biocompatibility, stability, and capacity to carry imaging payloads, render them well-suited for the precise and non-invasive diagnosis of CRC [71].”
BackgroundApplication of different nanoparticles in the diagnosis of colorectal cancer
Ghorbani, F., Kokhaei, P., Ghorbani, M., & Eslami, M. (2020) · Gene Reports · doi:10.1016/j.genrep.2020.100896 · Cited by 29 · cited 1×
“REVIEW Furthermore, these technologies can be customized to accommodate diverse sample types, including blood, tissue, and stool, extending their applicability in CRC diagnostics [56,57].”
BackgroundColorectal Cancer Diagnostic Methods: The Present and Future
Gude, S. S., Veeravalli, R. S., Vejandla, B., Gude, S. S., Venigalla, T., & Chintagumpala, V. (2023) · Cureus · doi:10.7759/cureus.37622 · Cited by 29 · cited 1×
“CRC diagnostic methods are typically classi fi ed into invasive and modalities (Figure 2). colonoscopy (CT colonography), and double-contrast barium enema [16].”
MethodXia, D., Hu, C., & Hou, Y. (2023) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2023.02.016 · Cited by 28 · cited 2×
“These findings collectively highlight the potential of SALN as a promising strategy for the treatment of CRC through enhanced lymphatic transport, offering prospects for clinical translation [73].”
BackgroundEstablishment of multiple diagnosis models for colorectal cancer with artificial neural networks
Wang, Q., Wei, J., Chen, Z., Zhang, T., Zhong, J., Zhong, B., Yang, P., Li, W., & Cao, J. (2019) · Oncology Letters · doi:10.3892/ol.2019.10010 · Cited by 27 · cited 1×
“For instance, a multiple diagnosis model for CRC using an artificial neural network has been established [104].”
MethodctDNA Detection in Microfluidic Platform: A Promising Biomarker for Personalized Cancer Chemotherapy
Gauri, S., & Ahmad, M. R. (2020) · Journal of Sensors · doi:10.1155/2020/8353674 · Cited by 27 · cited 1×
“The introduction of microfluidic-based liquid biopsies has had a transformative impact on early cancer detection and personalized medicine strategies, as evidenced by a comprehensive analysis of the existing literature [78,79].”
BackgroundLiu, Y., Jeraldo, P., Mendes‐Soares, H., Masters, T. L., Asangba, A. E., Nelson, H., Patel, R., Chia, N., & Walther-Antonio, M. R. S. (2021) · ACS Omega · doi:10.1021/acsomega.1c03683 · Cited by 27 · cited 1×
“In recent years, microfluidic technologies have emerged as a promising tool for disease diagnosis [10–12].”
MethodSelf-citationTowards Novel Non-Invasive Colorectal Cancer Screening Methods: A Comprehensive ReviewPreprint
Ferrari, A., Neefs, I., Hoeck, S., et al. (2021) · Preprints.org · doi:10.20944/preprints202103.0448.v1 · Cited by 26
Carbon‐Based Nanomaterials for Cancer Treatment and Diagnosis: A Review
Thomas, D. T., Baby, A., Raman, V., & Balakrishnan, S. P. (2022) · ChemistrySelect · doi:10.1002/slct.202202455 · Cited by 26 · cited 1×
“Compared with QDs and gold nanoparticles, the biocompatibility of carbon nanoparticles is a notable characteristic that ensures their safe administration in vivo without significant adverse health effects [62].”
BackgroundSakamoto, T., Mitsuzaki, K., Utsunomiya, D., Matsuda, K., Yamamura, S., Urata, J., Kawakami, M., & Yamashita, Y. (2012) · Acta Radiologica · doi:10.1258/ar.2012.110685 · Cited by 25 · cited 1×
“However, CT colonography has limitations in detecting sessile and flat polyps, which may lead to missed detections in certain cases [30–32].”
BackgroundMicrophysiological systems to study colorectal cancer: state-of-the-art
Ramos, P., Carvalho, M. R., Chen, W., Yan, L., Zhang, C., He, Y., Reis, R. L., & Oliveira, J. M. (2023) · Biofabrication · doi:10.1088/1758-5090/acc279 · Cited by 24 · cited 1×
“…technology with CRC represents a significant advancement with substantial potential for enhancing various aspects of CRC research, diagnosis, of biological samples, offering unique advantages such as enhanced sensitivity, high throughput, and improved control over experimental conditions [92].”
BackgroundAlrumaihi, F., Khan, M. A., Babiker, A. Y., Alsaweed, M., Azam, F., Allemailem, K. S., Almatroudi, A., Ahamad, S. R., Alsugoor, M. H., Alharbi, K. N., et al. (2022) · Molecules · doi:10.3390/molecules27072192 · Cited by 23 · cited 2×
“This study presents a promising approach for colorectal cancer prevention and treat-ment, highlighting the potential of DATSL and DOXL as a novel and efficient therapeutic strategy [72].”
BackgroundSu, W., Yu, H., Jiang, L., Chen, W., Li, H., & Qin, J. (2019) · Disease Markers · doi:10.1155/2019/8945974 · Cited by 21
Carbary-Ganz, J. L., Barton, J. K., & Utzinger, U. (2014) · Journal of Biomedical Optics · doi:10.1117/1.jbo.19.8.086003 · Cited by 20 · cited 2×
“This suggests the VEGFR2-targeted QDs demonstrated excellent imaging capabilities, providing enhanced contrast and improved visualization of CRC lesions compared to non-targeted QDs or conventional imaging agents [61].”
BackgroundVakil, N. B., Ciezki, K., Huq, N., & Singh, M. (2020) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2019.12.027 · Cited by 20 · cited 2×
“For instance, on the data from a comprehensive colon The stool DNA test o ff ers a sensitivity of 92% and a speci fi city of 87%, outperforming FIT detection [22]. cancer screening program, Vakil et al. [23 Various studies have used stool-based diagnostic approaches.”
BackgroundDolatkhah, R., Dastgiri, S., Jafarabadi, M. A., Abdolahi, H. M., & Somi, M. H. (2022) · Gastroenterología y Hepatología (English Edition) · doi:10.1016/j.gastrohep.2022.01.007 · Cited by 19 · cited 3×
“Similarly, Dolatkhah et al. [24] demonstrate a systematic review and meta-analysis to assess the diagnostic accuracy and reliability of multi-target stool DNA testing as a non-invasive method for CRC screening.”
BackgroundInfluentialLiu, Y., Li, S., & Liu, Y. (2022) · Cells · doi:10.3390/cells11050905 · Cited by 19 · cited 1×
“…alterations in biomarker levels or patterns of disease progression, thereby facilitating timely interventions and subsequently enhancing the long-term prospects for individuals grappling with CRC [102]. studies have demonstrated the effectiveness of AI in identifying novel biomarkers in CRC [103].”
BackgroundSelf-citationA New Size-based Platform for Circulating Tumor Cell Detection in Colorectal Cancer Patients
Oh, B. Y., Kim, J., Lee, W. Y., & Kim, H. C. (2017) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2017.01.007 · Cited by 17 · cited 1×
“For instance, a mi-crofluidic platform can integrate size-based filtration to isolate CTCs from peripheral blood samples from CRC patients, taking advantage of the size differences between CTCs and blood cells [80].”
BackgroundLoktionov, A. S., Soubières, A., Bandaletova, T. Y., Francis, N. K., Allison, J., Sturt, J., Mathur, J. B. L., & Poullis, A. P. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0893-8 · Cited by 14 · cited 1×
“Similarly, stool-based tests can be conveniently conducted at home, mitigating the challenges associated with conventional screening [39].”
BackgroundSun, J., & Zhang, G. (2019) · PubMed · Cited by 13
CT Colonography for Colorectal Cancer Screening
Ricci, Z. J., Kobi, M., & Yee, J. (2020) · Journal of Radiology Nursing · doi:10.1016/j.jradnu.2020.04.005 · Cited by 13
Frey, M. K., Ahsan, M. D., Badiner, N. M., Lin, J. J., Narayan, P., Nitecki, R., Rauh‐Hain, J. A., Moss, H. A., Fowlkes, R. K., Thomas, C., et al. (2022) · Cancer · doi:10.1002/cncr.34482 · Cited by 12 · cited 1×
“Long-Term Follow-Up: Long-term surveillance is of paramount importance, especially in the context of cancer diagnostics such as CRC. Vigilant, extended follow-up is imperative to evaluate the accuracy and efficacy of novel methods, thus prolonging the timeline required for widespread adoption [112].”
BackgroundAllameh, Z. S., Davari, M., & Emami, M. H. (2011) · Iranian Journal of Cancer Prevention · Cited by 10
Liu, Y., Yao, J. Z., & Walther-Antonio, M. R. S. (2019) · Biomicrofluidics · doi:10.1063/1.5090235 · Cited by 10
Self-citationAn action plan to address the rising burden of colorectal cancer in younger adults
Lowery, J. T., Weber, T. K., Ahnen, D. J., Schroy, P. C., Levell, C., & Smith, R. A. (2020) · Colorectal Cancer · doi:10.2217/crc-2020-0004 · Cited by 9 · cited 2×
“Additionally, emerging studies have drawn attention to a rising incidence of CRC in younger cohorts, with an estimated occurrence of 10% in this age bracket [3].”
BackgroundSmit, M. A., & Mesker, W. E. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.103070 · Cited by 9
Yao, T., Sun, Q., Xiong, K., Su, Y., Zhao, Q., Zhang, C., Zhang, L., Li, X., & Fang, H. (2023) · European Journal of Public Health · doi:10.1093/eurpub/ckad032 · Cited by 9 · cited 1×
“…tests such as fecal occult blood tests (FOBT), fecal immunochemical tests (FIT), and stool DNA tests, as well as standard diagnoses such as colonoscopy, which directly visualizes a biopsy of abnormal tissue or polyps, or computed tomographic colonography (CTC) as a less invasive alternative [7,8].”
BackgroundApplications of gold nano particle, quantum dot and magnetic nano particle
Jindal, S., & Jindal, S. (2023) · AIP conference proceedings · doi:10.1063/5.0121420 · Cited by 4 · cited 1×
“This is attributed to the unique physicochemical properties inherent in nanomaterials, which enable efficient biomarker capture and amplification due to their substantial surface area-to-volume ratio [54,55].”
Background
Cited by
Liquid biopsy in cancer management: Integrating diagnostics and clinical applications
Pandey, S., & Yadav, P. K. (2024) · Practical Laboratory Medicine · doi:10.1016/j.plabm.2024.e00446 · Cited by 131
Hemdan, M., Abuelhaded, K., Shaker, A. A. S., Ashour, M. M., Abdelaziz, M. M., Dahab, M. I., Nassar, Y. A., Sarguos, A. M. M., Zakaria, P. S., Fahmy, H. A., et al. (2025) · Sensing and Bio-Sensing Research · doi:10.1016/j.sbsr.2025.100783 · Cited by 56
Eslami, M., Naderian, R., Bahar, A., Babaeizad, A., Gheshlagh, S. R., Oksenych, V., & Tahmasebi, H. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1559480 · Cited by 60
Risk factors, prevention and screening of colorectal cancer: A rising problem
Tsukanov, V. V., Vasyutin, A. V., & Tonkikh, J. L. (2025) · World Journal of Gastroenterology · doi:10.3748/wjg.v31.i5.98629 · Cited by 42
AI-powered liquid biopsy for early detection of gastrointestinal cancers
Hussain, M. S., Rejili, M. S., Khan, A., Alshammari, S. O., Tan, C. S., Haouala, F., Ashique, S., & Alshammari, Q. A. (2025) · Clinica Chimica Acta · doi:10.1016/j.cca.2025.120484 · Cited by 31
Metadata
- Authors
- Beniwal, S., Lamo, P., Kaushik, A., Lorenzo-Villegas, D., Liu, Y., & MohanaSundaram, A.
- Affiliations
- Lady Hardinge Medical College (IN)
- Universidad Internacional de La Rioja (ES)
- Florida Polytechnic University (US)
- Universidad Fernando Pessoa Canarias (ES)
- Mayo Clinic (US)
- Sathyabama Institute of Science and Technology (IN)
- Corresponding author
- Liu, Yuguang
- MohanaSundaram, ArunSundar
- ORCID
- Venue
- Biosensors
- Publisher
- MDPI AG
- Published
- 2023-10-13
- Volume
- 13
- Issue
- 10
- Pages
- 926
- ISSN
- 2079-6374 (ISSN-L)
- PMC
- PMC10605407
- OpenAlex
- W4387642583
- Semantic Scholar
- 83019e80b94cab903d85130811d1120c47c81c75
- Cited by
- 60
- References
- 112
- Citations by year
- 2026: 17 · 2025: 24 · 2024: 19
- FWCI
- 1.35
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Biosensors (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Re-Unir (International University of La Rioja) (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Physical Sciences › Engineering › Biomedical Engineering › Microfluidic and Capillary Electrophoresis Applications
- Physical Sciences › Engineering › Biomedical Engineering › Biosensors and Analytical Detection
- Physical Sciences › Engineering › Biomedical Engineering › Microfluidic and Bio-sensing Technologies
- Keywords
- colorectal cancer, cancer screening, cancer diagnosis, microfluidics, artificial intelligence, early detection, non-invasive diagnosis, treatment response monitoring
- MeSH terms
- Artificial Intelligence, Humans, Technology, Colorectal Neoplasms, Microfluidics, Early Detection of Cancer
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.